EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2013 Annual Meeting Webcasts > Prostate Cancer > Module 2: Teaching Your Referring Physicians How to Interpret PSA Results and How to Find the Truth Beyond the Screening Controversy

Module 2: Teaching Your Referring Physicians How to Interpret PSA Results and How to Find the Truth Beyond the Screening Controversy

Introduction/Activity Overview Statement of Need

This course, building on the 2012 AUA PSA Town Hall, will provide participants with an understanding of how PSA testing has led to a fall in prostate cancer mortality, focusing on key findings—and limitations—of the PLCO and ERSPC trials. The course will address appropriate testing, test interpretation, and how to approach active surveillance and individualized therapy of prostate cancer. Strategies will be discussed to optimize protocols for screening and subsequent evaluation, both to reduce overdiagnosis of indolent disease and to maximize early detection of high-risk cases. Key "talking points" for communication with primary care providers will be emphasized.

Learning Objectives

After participating in this activity, participants should be able to:

  • critique the evidence and arguments for and against PSA-based screening for prostate cancer
  • describe the outcomes of the two large randomized trials in PSA testing and how trial design and confounders influenced these outcomes
  • describe the fall in prostate cancer mortality in the US since the inception of PSA testing and how modeling of these trends shows that about half of this fall is due to prostate cancer screening
  • describe the patient who is most likely to benefit from PSA testing and apply risk calculators, novel biomarkers, and other contemporary strategies in evaluating men with elevated PSA
  • interpret conclusions about PSA-based prostate cancer screening for referring primary providers

Faculty/Authors Disclosures

Matthew R. Cooperberg, MD, Director
Assistant Professor of Urology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Peter R. Carroll, MD, Faculty
Professor and Chair
University of California, San Francisco
San Francisco, CA

Ruth Etzioni, PhD, Faculty
Full Member
Fred Hutchinson Cancer Research Center
Seattle, WA

David F. Penson, MD, MPH, Faculty
Professor of Urologic Surgery
Vanderbilt University
Nashville, TN

Ian M. Thompson, Jr, MD, Co-Director
Director, Cancer Therapy and Research Center
The University of Texas Health Science Center at San Antonio
San Antonio, TX





Peter R. Carroll, MD NIH Scientific Study or Trial Yes
Matthew R. Cooperberg, MD Takeda Meeting Participant or Lecturer Yes
Ruth Etzioni, PhD Nothing to disclose    
David F. Penson, MD, MPH Nothing to disclose    
Ian M. Thompson, Jr, MD SWOG Leadership Position, Scientific Study or Trial No

Acknowledgement for Support

Support provided by educational grants from the following companies:

Abbvir Algeta AMGEN Astellas
Bayer Janseen Medivation Millennium

Matthew R. Cooperberg, MD
The "D" Recommendation: How did we get here?

Peter R. Carroll, MD
National Prostate Cancer Screening Guidelines: Will They/Have They Change(d)?

Ruth Etzioni, PhD
What We Can (and cannot) Learn From ERSPC and PLCO

David F. Penson, MD, MPH
Screening Policy: Lessons from mammography and a way forward for PSA screening

Ian M. Thompson, Jr, MD
Early Detection of Prostate Caner. Smarter, Targeted Approaches of 2013



Term of Use

© 2017 American Urological Association Education and Research Inc. All Rights Reserved.